GILEAD SCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GILEAD SCIENCES, INC. (GILD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $232.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $232.00M, a 2.65% increase year-over-year.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $218.00M, a 3.32% increase year-over-year.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $231.00M, a 4.52% increase year-over-year.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $231.00M, a 6.94% increase year-over-year.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $899.00M, a 7.79% increase from fiscal 2024.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $834.00M, a 8.74% increase from fiscal 2023.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $767.00M, a 19.84% increase from fiscal 2022.
- GILEAD SCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $640.00M, a 0.00% change from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $232.00M 10-Q · filed 2026-08-06 | $450.00M 10-Q · filed 2026-08-06 | $681.00M derived: sum of 3 quarters · filed 2026-08-06 | $912.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $218.00M 10-Q · filed 2026-05-07 | $449.00M derived: sum of 2 quarters · filed 2026-05-07 | $680.00M derived: sum of 3 quarters · filed 2026-05-07 | $906.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $231.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $462.00M derived: sum of 2 quarters · filed 2026-02-24 | $688.00M derived: sum of 3 quarters · filed 2026-08-06 | $899.00M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $231.00M 10-Q · filed 2025-11-07 | $457.00M derived: sum of 2 quarters · filed 2026-08-06 | $668.00M 10-Q · filed 2025-11-07 | $889.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $226.00M 10-Q · filed 2026-08-06 | $436.00M 10-Q · filed 2026-08-06 | $658.00M derived: sum of 3 quarters · filed 2026-08-06 | $874.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $211.00M 10-Q · filed 2026-05-07 | $432.00M derived: sum of 2 quarters · filed 2026-05-07 | $648.00M derived: sum of 3 quarters · filed 2026-05-07 | $857.00M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $221.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $437.00M derived: sum of 2 quarters · filed 2026-02-24 | $646.00M derived: sum of 3 quarters · filed 2026-02-24 | $834.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $216.00M 10-Q · filed 2025-11-07 | $425.00M derived: sum of 2 quarters · filed 2025-11-07 | $613.00M 10-Q · filed 2025-11-07 | $814.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $209.00M 10-Q · filed 2025-08-07 | $397.00M 10-Q · filed 2025-08-07 | $598.00M derived: sum of 3 quarters · filed 2026-02-24 | $800.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $188.00M 10-Q · filed 2025-05-07 | $389.00M derived: sum of 2 quarters · filed 2026-02-24 | $591.00M derived: sum of 3 quarters · filed 2026-02-24 | $789.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $201.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $403.00M derived: sum of 2 quarters · filed 2026-02-24 | $601.00M derived: sum of 3 quarters · filed 2026-02-24 | $767.00M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $202.00M 10-Q · filed 2024-11-12 | $400.00M derived: sum of 2 quarters · filed 2024-11-12 | $566.00M 10-Q · filed 2024-11-12 | $740.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $198.00M 10-Q · filed 2024-08-08 | $363.00M 10-Q · filed 2024-08-08 | $538.00M derived: sum of 3 quarters · filed 2025-02-28 | $708.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $165.00M 10-Q · filed 2024-05-08 | $340.00M derived: sum of 2 quarters · filed 2025-02-28 | $510.00M derived: sum of 3 quarters · filed 2025-02-28 | $674.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $175.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $345.00M derived: sum of 2 quarters · filed 2025-02-28 | $509.00M derived: sum of 3 quarters · filed 2025-02-28 | $640.00M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $170.00M 10-Q · filed 2023-11-07 | $334.00M derived: sum of 2 quarters · filed 2023-11-07 | $465.00M 10-Q · filed 2023-11-07 | $626.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | $164.00M 10-Q · filed 2023-08-04 | $295.00M 10-Q · filed 2023-08-04 | $456.00M derived: sum of 3 quarters · filed 2024-02-23 | $627.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $131.00M 10-Q · filed 2023-05-03 | $292.00M derived: sum of 2 quarters · filed 2024-02-23 | $463.00M derived: sum of 3 quarters · filed 2024-02-23 | $631.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $161.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $332.00M derived: sum of 2 quarters · filed 2024-02-23 | $500.00M derived: sum of 3 quarters · filed 2024-02-23 | $640.00M 10-K · filed 2024-02-23 | |
| 2021-09-30 | $171.00M 10-Q · filed 2022-11-02 | $339.00M derived: sum of 2 quarters · filed 2022-11-02 | $479.00M 10-Q · filed 2022-11-02 | $639.00M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | $168.00M 10-Q · filed 2022-08-08 | $308.00M 10-Q · filed 2022-08-08 | $468.00M derived: sum of 3 quarters · filed 2023-02-22 | $641.00M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $140.00M 10-Q · filed 2022-05-04 | $300.00M derived: sum of 2 quarters · filed 2023-02-22 | $473.00M derived: sum of 3 quarters · filed 2023-02-22 | $641.00M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $160.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $333.00M derived: sum of 2 quarters · filed 2023-02-22 | $501.00M derived: sum of 3 quarters · filed 2023-02-22 | $642.00M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $173.00M 10-Q · filed 2021-11-03 | $341.00M derived: sum of 2 quarters · filed 2021-11-03 | $482.00M 10-Q · filed 2021-11-03 | $641.00M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $168.00M 10-Q · filed 2021-08-05 | $309.00M 10-Q · filed 2021-08-05 | $468.00M derived: sum of 3 quarters · filed 2022-02-23 | $628.00M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $141.00M 10-Q · filed 2021-05-06 | $300.00M derived: sum of 2 quarters · filed 2022-02-23 | $460.00M derived: sum of 3 quarters · filed 2022-02-23 | $635.00M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $159.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $319.00M derived: sum of 2 quarters · filed 2022-02-23 | $494.00M derived: sum of 3 quarters · filed 2022-02-23 | $638.00M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $160.00M 10-Q · filed 2020-11-04 | $335.00M derived: sum of 2 quarters · filed 2020-11-04 | $479.00M 10-Q · filed 2020-11-04 | $654.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $175.00M 10-Q · filed 2020-08-06 | $319.00M 10-Q · filed 2020-08-06 | $494.00M derived: sum of 3 quarters · filed 2021-02-25 | $684.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $144.00M 10-Q · filed 2020-05-06 | $319.00M derived: sum of 2 quarters · filed 2021-02-25 | $509.00M derived: sum of 3 quarters · filed 2021-02-25 | $762.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $175.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $365.00M derived: sum of 2 quarters · filed 2021-02-25 | $618.00M derived: sum of 3 quarters · filed 2021-02-25 | $842.00M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $190.00M 10-Q · filed 2019-11-05 | $443.00M derived: sum of 2 quarters · filed 2019-11-05 | $667.00M 10-Q · filed 2019-11-05 | $980.00M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $253.00M 10-Q · filed 2019-08-06 | $477.00M 10-Q · filed 2019-08-06 | $790.00M derived: sum of 3 quarters · filed 2020-02-25 | $904.00M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $224.00M 10-Q · filed 2019-05-08 | $537.00M derived: sum of 2 quarters · filed 2020-02-25 | $651.00M derived: sum of 3 quarters · filed 2020-02-25 | $753.00M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2017-12-31 | $313.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $427.00M derived: sum of 2 quarters · filed 2020-02-25 | $529.00M derived: sum of 3 quarters · filed 2020-02-25 | $618.00M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $114.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $216.00M derived: sum of 2 quarters · filed 2017-11-07 | $305.00M 10-Q · filed 2017-11-07 | $408.00M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $102.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $191.00M 10-Q · filed 2017-08-07 | $294.00M derived: sum of 3 quarters · filed 2019-02-26 | $389.00M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $89.00M 10-Q · filed 2017-05-10 | $192.00M derived: sum of 2 quarters · filed 2019-02-26 | $287.00M derived: sum of 3 quarters · filed 2019-02-26 | $382.00M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $103.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $198.00M derived: sum of 2 quarters · filed 2019-02-26 | $293.00M derived: sum of 3 quarters · filed 2019-02-26 | $381.00M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $95.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $190.00M derived: sum of 2 quarters · filed 2016-11-07 | $278.00M 10-Q · filed 2016-11-07 | $377.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $95.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $183.00M 10-Q · filed 2016-08-05 | $282.00M derived: sum of 3 quarters · filed 2018-02-27 | $379.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $88.00M 10-Q · filed 2016-05-06 | $187.00M derived: sum of 2 quarters · filed 2018-02-27 | $284.00M derived: sum of 3 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $196.00M derived: sum of 2 quarters · filed 2018-02-27 | $384.00M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $97.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $285.00M 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | $188.00M 10-Q · filed 2015-08-05 | ||||
| 2014-12-31 | $362.00M 10-K · filed 2017-02-27 | ||||
| 2013-12-31 | $254.00M 10-K · filed 2016-02-24 | $254.32M 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $208.00M 10-K · filed 2015-02-25 | $208.23M 10-K · filed 2014-02-25 | |||
| 2011-12-31 | $192.03M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |